Adrien Tuwisana Masunda
Research Subjects
Adrien Tuwisana Masunda has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Aristote Matondo
Department of Chemistry, Faculty of Sciences and Technology, University of Kinshasa, & Research Centre for Pharmacopoeia and Traditional Medicine (CRPMT), Higher Institute of Medical Techniques of Kinshasa, Kinshasa, Democratic Republic of the Congo
1 shared publication - Benjamin Gbolo Zoawe
Department of Biology, Faculty of Sciences, University of Kinshasa
1 shared publication - Colette Ashande Masengo
Institut Supérieur des Techniques Médicales de KKinshasa
1 shared publication - Damien Sha-Tshibey Tshibangu
Department of Chemistry, Faculty of Sciences, University of Kinshasa
1 shared publication - Dorothée D. Tshilanda
Faculté des Sciences, Université de Kinshasa, B.P. 190 Kinshasa XI, DR Congo
1 shared publication - Emmanuel Moke Lengbiye1 shared publication
Latest Publications
- Open Access
- 16 January 2022
- Published by Visagaa Publishing House in Natural Resources for Human Health
- Vol. 2 (2) , 265-273
Glucose oxidase as a model enzyme for antidiabetic activity evaluation of medicinal plants: In vitro and in silico evidence
Diabetes mellitus is a major public health problem in the world. In Africa, more than 80% of patients use plants for their treatment. However, the methods of validation of endogenous knowledge usually used are costly. The alternative method developed in this study aims at creating hyperglycemia in vitro and exploiting the metabolic pathway involving glucose oxidase for UV-visible spectrophotometric screening of medicinal plants’ antidiabetic activity. The evolution of glucose oxidation as a function of drug concentration is followed by UV-visible spectrophotometry. The formation of the stable complex between the enzyme and the inhibitor is studied using molecular docking. Drugs used (Gliben) and plant extracts exhibited an in vitro hypoglycemic effect by reducing exponentially, in vitro, the level of free glucose. The results also showed that L. multiflora is more active than V. amygdalina (IC50: 1.36 ± 0.09 mg/mL Vs IC50: 3.00 ± 0.54 mg/mL). Gliben (0.5 mg/mL) and L. multiflora (2 mg/mL) reduced both the rate of oxidation of glucose by glucose oxidase (catalytic power Vmax: 0.84 ± 0.11 mg*mL-1*min-1 for Gliben and 1.72 ± 0.13 mg*mL-1*min-1 for L. multiflora); and the affinity of this enzyme for its substrate-glucose (KM: 15.11 ± 2.72 mg*mL-1 for Gliben and 9.17 ± 1.56 mg*mL-1 for L. multiflora) when these results are compared to enzyme catalysis in the absence of inhibitor (Vmax: 2.86 ± 0.44 mg*mL-1*min-1; KM: 8.07 ± 1.96 mg*mL-1). The binding of GOX (1GAL) to selected phytocompounds derived from L. multiflora was confirmed by molecular docking. The most stable complexes were obtained for four compounds; 8 (-10.1±0.0 Kcal/mol), 6 (-9.5±0.1 Kcal/mol), 3 (-8.3±0.0 Kcal/mol) and 9 (-8.2±0.1 Kcal/mol). Among these, compounds 8 and 6 formed complexes with the enzyme stabilized by hydrogen bonds, the compound 8 forms 5 hydrogen bonds (ASN514, ASP424, ARG95, TYP68, LEU65) while compound 6 forms 2 hydrogen bonds (ASN514 and SER422). However, no H-bonding interaction occurs in the complex that involves ligands 9 and 3 despite their high binding energy (-8.2±0.1 Kcal/mol and -8.3±0.0 Kcal/mol respectively). Glucose oxidase can serve as a marker enzyme for in vitro antidiabetic activity evaluation of medicinal plants.
- 16 January 2022
- Published by Visagaa Publishing House in Natural Resources for Human Health
- Vol. 2 (2) , 265-273
Open AccessGlucose oxidase as a model enzyme for antidiabetic activity evaluation of medicinal plants: In vitro and in silico evidence
Diabetes mellitus is a major public health problem in the world. In Africa, more than 80% of patients use plants for their treatment. However, the methods of validation of endogenous knowledge usually used are costly. The alternative method developed in this study aims at creating hyperglycemia in vitro and exploiting the metabolic pathway involving glucose oxidase for UV-visible spectrophotometric screening of medicinal plants’ antidiabetic activity. The evolution of glucose oxidation as a function of drug concentration is followed by UV-visible spectrophotometry. The formation of the stable complex between the enzyme and the inhibitor is studied using molecular docking. Drugs used (Gliben) and plant extracts exhibited an in vitro hypoglycemic effect by reducing exponentially, in vitro, the level of free glucose. The results also showed that L. multiflora is more active than V. amygdalina (IC50: 1.36 ± 0.09 mg/mL Vs IC50: 3.00 ± 0.54 mg/mL). Gliben (0.5 mg/mL) and L. multiflora (2 mg/mL) reduced both the rate of oxidation of glucose by glucose oxidase (catalytic power Vmax: 0.84 ± 0.11 mg*mL-1*min-1 for Gliben and 1.72 ± 0.13 mg*mL-1*min-1 for L. multiflora); and the affinity of this enzyme for its substrate-glucose (KM: 15.11 ± 2.72 mg*mL-1 for Gliben and 9.17 ± 1.56 mg*mL-1 for L. multiflora) when these results are compared to enzyme catalysis in the absence of inhibitor (Vmax: 2.86 ± 0.44 mg*mL-1*min-1; KM: 8.07 ± 1.96 mg*mL-1). The binding of GOX (1GAL) to selected phytocompounds derived from L. multiflora was confirmed by molecular docking. The most stable complexes were obtained for four compounds; 8 (-10.1±0.0 Kcal/mol), 6 (-9.5±0.1 Kcal/mol), 3 (-8.3±0.0 Kcal/mol) and 9 (-8.2±0.1 Kcal/mol). Among these, compounds 8 and 6 formed complexes with the enzyme stabilized by hydrogen bonds, the compound 8 forms 5 hydrogen bonds (ASN514, ASP424, ARG95, TYP68, LEU65) while compound 6 forms 2 hydrogen bonds (ASN514 and SER422). However, no H-bonding interaction occurs in the complex that involves ligands 9 and 3 despite their high binding energy (-8.2±0.1 Kcal/mol and -8.3±0.0 Kcal/mol respectively). Glucose oxidase can serve as a marker enzyme for in vitro antidiabetic activity evaluation of medicinal plants.